Authors
Daniel M Jones, Sarah C Gilbert
Published in
Current opinion in virology. Volume 77. Pages 101595. Nov 12, 2026. Epub Nov 12, 2026.
Abstract
Vaccine platforms are validated, adaptable technologies designed to enable a 'plug-and-play' approach to vaccine development and deployment, and have emerged as a cornerstone for epidemic and pandemic preparedness due to their capacity to be rapidly tailored to emerging pathogens. This capability was demonstrated during the COVID-19 pandemic, when the first clinical trial of a SARS-CoV-2 vaccine was initiated just 66 days after the viral genome was published. However, outbreaks caused by novel emerging viruses like SARS-CoV-2 are less common than those caused by known, re-emerging pathogens, including Marburg, Nipah and Lassa viruses. Unlike SARS-CoV-2, these pathogens have been recognised as public health threats for decades, yet licensed vaccines against them have yet to be realised. While this gap is partly attributable to scientific shortfalls, a more significant factor has arguably been the combination of economic, regulatory and epidemiological challenges that have impeded vaccine licensure and stockpile establishment. This review discusses how vaccine platforms are addressing some of these challenges, potentially providing the foundation for much-needed vaccine stockpiling approaches against re-emerging pathogens.
PMID:
43019871
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0